David Ricks - Eli Lilly President

LLY Stock  MXN 15,422  5.88  0.04%   

President

Mr. David A. Ricks is the Chairman of the Board, President, Chief Executive Officer of the Company. Mr. Ricks was named President and CEO on January 1, 2017, and joined the board at that time. He became Chairman of the Board on June 1, 2017 since 2017.
Age 55
Tenure 7 years
Phone317 276 2000
Webhttps://www.lilly.com
Ricks joined Lilly in 1996 and most recently served as president of Lilly BioMedicines. He has deep expertise in product development, global sales and marketing, as well as public policy. He has significant global experience in the company commercial operations.

Eli Lilly Management Efficiency

The company has return on total asset (ROA) of 0.1148 % which means that it generated a profit of $0.1148 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.6464 %, meaning that it generated $0.6464 on every $100 dollars invested by stockholders. Eli Lilly's management efficiency ratios could be used to measure how well Eli Lilly manages its routine affairs as well as how well it operates its assets and liabilities.
Eli Lilly and has accumulated 15.35 B in total debt with debt to equity ratio (D/E) of 648.2, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Eli Lilly has a current ratio of 1.1, suggesting that it may not be capable to disburse its financial obligations in time and when they become due. Debt can assist Eli Lilly until it has trouble settling it off, either with new capital or with free cash flow. So, Eli Lilly's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Eli Lilly sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Eli to invest in growth at high rates of return. When we think about Eli Lilly's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 12 records

PRESIDENT Age

Ann JudgeBristol Myers Squibb
57
Murdo GordonAmgen Inc
56
Andrew DickinsonGilead Sciences
53
Ginger GregoryBiogen Inc
55
Sanjay JariwalaBiogen Inc
N/A
JeanBaptiste ChatillonSanofi
58
Anabella VillalobosBiogen Inc
64
Esteban SantosAmgen Inc
55
Christopher BoernerBristol Myers Squibb
52
Richard DeLucaMerck Company
60
Robin KramerBiogen Inc
57
Jonathan GrahamAmgen Inc
62
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana. ELI LILLY operates under Drug Manufacturers - Major classification in Mexico and is traded on Mexico Stock Exchange. It employs 33610 people. Eli Lilly and (LLY) is traded on Mexican Exchange in Mexico and employs 47 people.

Management Performance

Eli Lilly Leadership Team

Elected by the shareholders, the Eli Lilly's board of directors comprises two types of representatives: Eli Lilly inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Eli. The board's role is to monitor Eli Lilly's management team and ensure that shareholders' interests are well served. Eli Lilly's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Eli Lilly's outside directors are responsible for providing unbiased perspectives on the board's policies.
David Ricks, Senior Vice President and Presidentident - Lilly Bio-Medicines
Alonzo Weems, VP Officer
Jacob Naarden, CEO VP
Diogo Rau, VP Officer
Donald Zakrowski, Chief Fin
Anat Ashkenazi, VP CFO
Leigh Pusey, Senior Vice President - Corporate Affairs and Communications
Martin MIBS, VP Projects
Anat JD, Gen VP

Eli Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Eli Lilly a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Eli Stock Analysis

When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.